HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Urokinase-controlled tumor penetrating peptide.

Abstract
Tumor penetrating peptides contain a cryptic (R/K)XX(R/K) CendR element that must be C-terminally exposed to trigger neuropilin-1 (NRP-1) binding, cellular internalization and malignant tissue penetration. The specific proteases that are involved in processing of tumor penetrating peptides identified using phage display are not known. Here we design de novo a tumor-penetrating peptide based on consensus cleavage motif of urokinase-type plasminogen activator (uPA). We expressed the peptide, uCendR (RPARSGR↓SAGGSVA, ↓ shows cleavage site), on phage or coated it onto silver nanoparticles and showed that it is cleaved by uPA, and that the cleavage triggers binding to recombinant NRP-1 and to NPR-1-expressing cells. Upon systemic administration to mice bearing uPA-overexpressing breast tumors, FAM-labeled uCendR peptide and uCendR-coated nanoparticles preferentially accumulated in tumor tissue. We also show that uCendR phage internalization into cultured cancer cells and its penetration in explants of murine tumors and clinical tumor explants can be potentiated by combining the uCendR peptide with tumor-homing module, CRGDC. Our work demonstrates the feasibility of designing tumor-penetrating peptides that are activated by a specific tumor protease. As upregulation of protease expression is one of the hallmarks of cancer, and numerous tumor proteases have substrate specificities compatible with proteolytic unmasking of cryptic CendR motifs, the strategy described here may provide a generic approach for designing proteolytically-actuated peptides for tumor-penetrative payload delivery.
AuthorsGary B Braun, Kazuki N Sugahara, Olivia M Yu, Venkata Ramana Kotamraju, Tarmo Mölder, Andrew M Lowy, Erkki Ruoslahti, Tambet Teesalu
JournalJournal of controlled release : official journal of the Controlled Release Society (J Control Release) Vol. 232 Pg. 188-95 (06 28 2016) ISSN: 1873-4995 [Electronic] Netherlands
PMID27106816 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016 Elsevier B.V. All rights reserved.
Chemical References
  • Drug Carriers
  • Peptides
  • Silver
  • Urokinase-Type Plasminogen Activator
Topics
  • Animals
  • Bacteriophage T7
  • Cell Line, Tumor
  • Drug Carriers (administration & dosage, pharmacokinetics)
  • Humans
  • Mammary Neoplasms, Animal (metabolism)
  • Metal Nanoparticles (administration & dosage)
  • Mice, Inbred BALB C
  • Peptides (administration & dosage, pharmacokinetics)
  • Silver (administration & dosage, pharmacokinetics)
  • Urokinase-Type Plasminogen Activator (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: